Literature DB >> 30268666

Astaxanthin ameliorates experimental diabetes-induced renal oxidative stress and fibronectin by upregulating connexin43 in glomerular mesangial cells and diabetic mice.

Qing Chen1, Jun Tao1, Guoping Li2, Dongxiao Zheng3, Yao Tan3, Ruibo Li3, Li Tian3, Zhanghao Li3, Haotian Cheng3, Xi Xie4.   

Abstract

Oxidative stress is the major cause of renal fibrosis in the progression of DN. Connexin43 (Cx43) exerts an anti-fibrosis effect on diabetic kidneys. The current study aimed to investigate whether astaxanthin (AST) could ameliorate the pathological progression of DN by upregulating Cx43 and activating the Nrf2/ARE signaling, which is a pivotal anti-oxidative stress system, to strengthen the cellular anti-oxidative capacity and diminish fibronectin (FN) accumulation in HG-induced glomerular mesangial cells (GMCs). Our hypothesis was verified in GMCs and the kidneys from db/db mice by western blot, immunofluorescence, immunohistochemistry, immunoprecipitation, dual luciferase reporter assay and reactive oxygen related detection kits. Results showed that AST simultaneously upregulated the Cx43 protein level and promoted the Nrf2/ARE signaling activity in the kidney of db/db mice and HG-treated GMCs. However, Cx43 depletion abrogated the Nrf2/ARE signaling activation induced by AST. AST reduced the interaction between c-Src and Nrf2 in the nuclei of GMCs cultured with HG, thereby enhancing the Nrf2 accumulation in the nuclei of GMCs. Our data suggested that AST promoted the Nrf2/ARE signaling by upregulating the Cx43 protein level to prevent renal fibrosis triggered by HG in GMCs and db/db mice. c-Src acted as a mediator in these processes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Astaxanthin; Connexin43; Diabetic nephropathy; Nrf2/ARE signaling; Renal fibrosis

Mesh:

Substances:

Year:  2018        PMID: 30268666     DOI: 10.1016/j.ejphar.2018.09.028

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Expression of Pannexin 1 in the Human Kidney during Embryonal, Early Fetal and Postnatal Development and Its Prognostic Significance in Diabetic Nephropathy.

Authors:  Ivo Jeličić; Katarina Vukojević; Anita Racetin; Davor Čarić; Merica Glavina Durdov; Mirna Saraga-Babić; Natalija Filipović
Journal:  Biomedicines       Date:  2022-04-20

Review 2.  Impact of Astaxanthin on Diabetes Pathogenesis and Chronic Complications.

Authors:  Rebecca Landon; Virginie Gueguen; Hervé Petite; Didier Letourneur; Graciela Pavon-Djavid; Fani Anagnostou
Journal:  Mar Drugs       Date:  2020-07-09       Impact factor: 5.118

3.  Astaxanthin ameliorates renal interstitial fibrosis and peritubular capillary rarefaction in unilateral ureteral obstruction.

Authors:  Jin Zhao; Meixia Meng; Jinhua Zhang; Lili Li; Xiaojing Zhu; Li Zhang; Chang Wang; Ming Gao
Journal:  Mol Med Rep       Date:  2019-02-19       Impact factor: 2.952

Review 4.  Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging.

Authors:  Mónika Sztretye; Beatrix Dienes; Mónika Gönczi; Tamás Czirják; László Csernoch; László Dux; Péter Szentesi; Anikó Keller-Pintér
Journal:  Oxid Med Cell Longev       Date:  2019-11-11       Impact factor: 6.543

5.  The Probable, Possible, and Novel Functions of ERp29.

Authors:  Margaret Brecker; Svetlana Khakhina; Tyler J Schubert; Zachary Thompson; Ronald C Rubenstein
Journal:  Front Physiol       Date:  2020-09-08       Impact factor: 4.566

Review 6.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

7.  PP2 Ameliorates Renal Fibrosis by Regulating the NF-κB/COX-2 and PPARγ/UCP2 Pathway in Diabetic Mice.

Authors:  Jinying Wei; Xinna Deng; Yang Li; Runmei Li; Zhaohua Yang; Xiuyuan Li; Shan Song; Yonghong Shi; Huijun Duan; Haijiang Wu
Journal:  Oxid Med Cell Longev       Date:  2021-09-17       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.